Personalized chemotherapy for low-grade bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have bladder cancer that is low-grade or grade 2 (not high-grade).
- You are not taking blood thinners (except low-dose aspirin).
- You have not had a serious infection in the last 4 weeks.
- You are not pregnant or breastfeeding, and you are willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.